Heidemarie Huber

2.6k total citations
37 papers, 2.1k citations indexed

About

Heidemarie Huber is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Heidemarie Huber has authored 37 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 14 papers in Molecular Biology and 11 papers in Immunology. Recurrent topics in Heidemarie Huber's work include Liver physiology and pathology (11 papers), Phagocytosis and Immune Regulation (8 papers) and Pancreatic and Hepatic Oncology Research (6 papers). Heidemarie Huber is often cited by papers focused on Liver physiology and pathology (11 papers), Phagocytosis and Immune Regulation (8 papers) and Pancreatic and Hepatic Oncology Research (6 papers). Heidemarie Huber collaborates with scholars based in Austria, Germany and United States. Heidemarie Huber's co-authors include Wolfgang Mikulits, Hartmut Beug, Michaela Petz, Franziska van Zijl, Doris Schneller, Gudrun Zulehner, Mario Mikula, Markus Grubinger, Nicole C.C. Them and Josef Gotzmann and has published in prestigious journals such as Nucleic Acids Research, Blood and PLoS ONE.

In The Last Decade

Heidemarie Huber

36 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Heidemarie Huber Austria 21 1.2k 828 404 380 353 37 2.1k
Esther Bertrán Spain 24 1.5k 1.2× 681 0.8× 398 1.0× 308 0.8× 473 1.3× 43 2.3k
Chamelli Jhappan United States 18 1.7k 1.4× 1.1k 1.3× 177 0.4× 242 0.6× 316 0.9× 21 2.6k
Raleigh D. Kladney United States 23 996 0.8× 505 0.6× 219 0.5× 281 0.7× 434 1.2× 33 1.8k
Ling-Mei Wang United States 18 962 0.8× 592 0.7× 191 0.5× 487 1.3× 219 0.6× 32 1.8k
Orlando Musso France 23 812 0.7× 427 0.5× 403 1.0× 138 0.4× 478 1.4× 40 1.6k
Ning T. Yeh United States 12 1.1k 0.9× 855 1.0× 146 0.4× 360 0.9× 684 1.9× 12 2.0k
Changcun Guo China 27 1.4k 1.1× 451 0.5× 173 0.4× 357 0.9× 582 1.6× 72 2.3k
Giacomo Manenti Italy 30 1.8k 1.5× 811 1.0× 132 0.3× 209 0.6× 590 1.7× 102 3.0k
Chiara Raggi Italy 24 924 0.8× 681 0.8× 329 0.8× 241 0.6× 563 1.6× 54 1.9k
Efi E. Massasa United States 14 1.2k 1.0× 397 0.5× 303 0.8× 529 1.4× 276 0.8× 15 2.4k

Countries citing papers authored by Heidemarie Huber

Since Specialization
Citations

This map shows the geographic impact of Heidemarie Huber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heidemarie Huber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heidemarie Huber more than expected).

Fields of papers citing papers by Heidemarie Huber

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heidemarie Huber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heidemarie Huber. The network helps show where Heidemarie Huber may publish in the future.

Co-authorship network of co-authors of Heidemarie Huber

This figure shows the co-authorship network connecting the top 25 collaborators of Heidemarie Huber. A scholar is included among the top collaborators of Heidemarie Huber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heidemarie Huber. Heidemarie Huber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Huber, Heidemarie, et al.. (2023). PRAME Is a Novel Target of Tumor-Intrinsic Gas6/Axl Activation and Promotes Cancer Cell Invasion in Hepatocellular Carcinoma. Cancers. 15(9). 2415–2415. 12 indexed citations
2.
Chen, Doris, Eva Řezníčková, Heidemarie Huber, et al.. (2023). Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma. Frontiers in Oncology. 13. 1238883–1238883. 4 indexed citations
3.
Staufer, Katharina, Heidemarie Huber, Rodrig Marculescu, et al.. (2017). The non-invasive serum biomarker soluble Axl accurately detects advanced liver fibrosis and cirrhosis. Cell Death and Disease. 8(10). e3135–e3135. 40 indexed citations
4.
Huber, Heidemarie, et al.. (2016). Accurate Determination of Soluble Axl by Enzyme-Linked Immunosorbent Assay. Assay and Drug Development Technologies. 14(9). 543–550. 11 indexed citations
5.
Grubinger, Markus, et al.. (2015). Neuropilin-2 induced by transforming growth factor-β augments migration of hepatocellular carcinoma cells. BMC Cancer. 15(1). 909–909. 28 indexed citations
6.
Petz, Michaela, Nicole C.C. Them, Heidemarie Huber, & Wolfgang Mikulits. (2012). PDGF enhances IRES-mediated translation of Laminin B1 by cytoplasmic accumulation of La during epithelial to mesenchymal transition. Nucleic Acids Research. 40(19). 9738–9749. 47 indexed citations
7.
Petz, Michaela, Nicole C.C. Them, Heidemarie Huber, Hartmut Beug, & Wolfgang Mikulits. (2011). La enhances IRES-mediated translation of laminin B1 during malignant epithelial to mesenchymal transition. Nucleic Acids Research. 40(1). 290–302. 188 indexed citations
8.
Schneller, Doris, Georg Machat, Verena Proell, et al.. (2011). p19ARF/p14ARF controls oncogenic functions of signal transducer and activator of transcription 3 in hepatocellular carcinoma. Hepatology. 54(1). 164–172. 40 indexed citations
9.
Zijl, Franziska van, Gudrun Zulehner, Michaela Petz, et al.. (2009). Epithelial–Mesenchymal Transition in Hepatocellular Carcinoma. Future Oncology. 5(8). 1169–1179. 264 indexed citations
10.
Zulehner, Gudrun, Mario Mikula, Doris Schneller, et al.. (2009). Nuclear β-Catenin Induces an Early Liver Progenitor Phenotype in Hepatocellular Carcinoma and Promotes Tumor Recurrence. American Journal Of Pathology. 176(1). 472–481. 76 indexed citations
11.
Petz, Michaela, Heidemarie Huber, Tanja Siwiec, et al.. (2007). The leader region of Laminin B1 mRNA confers cap-independent translation. Nucleic Acids Research. 35(8). 2473–2482. 24 indexed citations
13.
Gotzmann, Josef, Andreas Fischer, Markus Zojer, et al.. (2006). A crucial function of PDGF in TGF-β-mediated cancer progression of hepatocytes. Oncogene. 25(22). 3170–3185. 171 indexed citations
14.
Fischer, Andreas, et al.. (2006). PDGF essentially links TGF-β signaling to nuclear β-catenin accumulation in hepatocellular carcinoma progression. Oncogene. 26(23). 3395–3405. 119 indexed citations
15.
Mikula, Mario, et al.. (2004). Immortalized p19ARF null hepatocytes restore liver injury and generate hepatic progenitors after transplantation. Hepatology. 39(3). 628–634. 29 indexed citations
16.
Zöchbauer‐Müller, Sabine, J. Wallner, K. Haider, et al.. (1997). MDR1 RNA transcripts do not indicate long-term prognosis in colorectal carcinomas. European Journal of Cancer. 33(9). 1516–1518. 5 indexed citations
17.
Malayeri, R., Thomas Berger, A. Doppelbauer, et al.. (1996). 26 P - Monitoring of neurotoxicity of taxanes. European Journal of Cancer. 32. S6–S6.
18.
Grunt, Thomas W. & Heidemarie Huber. (1994). The Family of c-<i>erb</i>B Genes: From Basic Research to Clinical Oncology. Oncology Research and Treatment. 17(4). 346–357. 10 indexed citations
19.
Gattringer, C., J. Thaler, Johannes Drach, M. Micksche, & Heidemarie Huber. (1989). GM-CSF Treatment in Aplasia after Cytotoxic Therapy. Oncology Research and Treatment. 12(1). 16–18. 7 indexed citations
20.
Brieskorn, Carl Heinz & Heidemarie Huber. (1976). Vier neue lignane aus aptosimum spinescens ( Thunbg. ). Tetrahedron Letters. 17(26). 2221–2224. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026